Cargando…
Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells
Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we inve...
Autores principales: | Mohammadian, Jamal, Sabzichi, Mehdi, Molavi, Ommoleila, Shanehbandi, Dariush, Samadi, Nasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454715/ https://www.ncbi.nlm.nih.gov/pubmed/28032735 http://dx.doi.org/10.22034/APJCP.2016.17.11.5031 |
Ejemplares similares
-
Folate-Targeted Nanostructured Lipid Carriers (NLCs) Enhance (Letrozol) Efficacy in MCF-7 Breast Cancer Cells
por: Sabzichi, Mehdi, et al.
Publicado: (2016) -
Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia
por: Vucicevic, Ksenija, et al.
Publicado: (2016) -
Heartwood extract of Acacia catechu induces apoptosis in human breast carcinoma by altering bax/bcl-2 ratio
por: Ghate, Nikhil Baban, et al.
Publicado: (2014) -
Bax/Bcl-2 expression ratio in prediction of response to breast cancer radiotherapy
por: Azimian, Hosein, et al.
Publicado: (2018) -
Sphingosine 1-phosphate interacts with Survivin pathway to enhance tumorigenesis in cancer cells
por: Tabasinezhad, Maryam, et al.
Publicado: (2015)